Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook
Key PointsIonis has six commercial therapies, mostly focused on rare diseases.
Investors have been selling off shares of Ionis Pharmaceuticals (NASDAQ: IONS), causing the company's stock price to plummet more than 40% this year. The stock has reached a low point, hovering just below half of its 52-week high of $86.74. Despite the recent decline, analysts remain optimistic about Ionis' future prospects. They have collectively set a high price target of $83.82 for the stock, with most rating it as a buy or a strong buy.
Ionis Pharmaceuticals specializes in developing therapies for neurological disorders and cardiometabolic diseases, holding six FDA-approved treatments for rare diseases. The company's portfolio includes Zanvastro for Alexander disease, Dawnzera for hereditary angioedema, Qalsody for amyotrophic lateral sclerosis (ALS), Spinraza for spinal muscular atrophy, Wainua for amyloid plaque reduction, and Triglycerol for adults with high triglycerides.
The disparity between retail investors' and analysts' perspectives on Ionis Pharmaceuticals' stock price is evident. To better understand the reasons behind the stock's decline and its potential as a sound investment, further examination is required.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
